Salix Pharmaceuticals Company Profile (NASDAQ:SLXP)

About Salix Pharmaceuticals (NASDAQ:SLXP)

Salix Pharmaceuticals logoSalix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:SLXP
  • CUSIP: 79543510
  • Web: www.salix.com
Average Prices:
  • 50 Day Moving Avg: $173.00
  • 200 Day Moving Avg: $133.00
  • 52 Week Range: $86.00 - $173.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 18.78
  • P/E Growth: 0
Profitability:
  • Net Margins: -2,134.34%
  • Return on Equity: -305.24%
  • Return on Assets: -25.83%
Misc:
  • Average Volume: 3.35 million shs.
 
Frequently Asked Questions for Salix Pharmaceuticals (NASDAQ:SLXP)

What is Salix Pharmaceuticals' stock symbol?

Salix Pharmaceuticals trades on the NASDAQ under the ticker symbol "SLXP."

How were Salix Pharmaceuticals' earnings last quarter?

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) released its earnings results on Monday, March, 2nd. The company reported ($2.61) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.29) by $2.32. The company earned $13 million during the quarter, compared to analysts' expectations of $187.97 million. Salix Pharmaceuticals had a negative net margin of 2,134.34% and a negative return on equity of 305.24%. During the same quarter last year, the business posted $1.06 earnings per share. View Salix Pharmaceuticals' Earnings History.

Who are some of Salix Pharmaceuticals' key competitors?

How do I buy Salix Pharmaceuticals stock?

Shares of Salix Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Salix Pharmaceuticals' stock price today?

One share of Salix Pharmaceuticals stock can currently be purchased for approximately $169.00.


MarketBeat Community Rating for Salix Pharmaceuticals (NASDAQ SLXP)
Community Ranking:  2.7 out of 5 ( )
Outperform Votes:  286 (Vote Outperform)
Underperform Votes:  235 (Vote Underperform)
Total Votes:  521
MarketBeat's community ratings are surveys of what our community members think about Salix Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Salix Pharmaceuticals (NASDAQ:SLXP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Salix Pharmaceuticals (NASDAQ:SLXP)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Salix Pharmaceuticals (NASDAQ:SLXP)
Earnings by Quarter for Salix Pharmaceuticals (NASDAQ:SLXP)
Earnings History by Quarter for Salix Pharmaceuticals (NASDAQ SLXP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/2/2015Q414($0.29)($2.61)$187.97 million$13.00 millionViewN/AView Earnings Details
11/6/2014Q314$1.56$1.53$394.00 million$354.70 millionViewN/AView Earnings Details
8/7/2014Q214$1.69$1.59$397.06 million$382.00 millionViewListenView Earnings Details
5/8/2014Q114$0.91$1.05$372.91 million$384.00 millionViewListenView Earnings Details
2/27/2014Q413$0.93$1.06$247.29 million$257.60 millionViewListenView Earnings Details
11/7/2013Q313$0.86$0.89$239.70 million$238.20 millionViewN/AView Earnings Details
8/8/2013Q2 2013$0.81$0.87$226.34 million$235.40 millionViewListenView Earnings Details
5/9/2013Q1 2013$0.67$0.63$205.94 million$202.60 millionViewListenView Earnings Details
2/28/2013Q4 2012$0.78$0.81$199.41 million$198.17 millionViewN/AView Earnings Details
11/7/2012Q312$0.69$0.95$187.23 million$185.13 millionViewN/AView Earnings Details
8/8/2012$0.54$0.79ViewN/AView Earnings Details
5/7/2012$0.56$0.67ViewN/AView Earnings Details
11/8/2011$0.60$0.77ViewN/AView Earnings Details
8/8/2011$0.44$0.32ViewN/AView Earnings Details
5/5/2011$0.17$0.34ViewN/AView Earnings Details
2/28/2011$0.49$0.66ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Salix Pharmaceuticals (NASDAQ:SLXP)
Current Year EPS Consensus Estimate: $4 EPS
Next Year EPS Consensus Estimate: $9 EPS

Dividends

Dividend History for Salix Pharmaceuticals (NASDAQ:SLXP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Salix Pharmaceuticals (NASDAQ:SLXP)
Insider Trades by Quarter for Salix Pharmaceuticals (NASDAQ:SLXP)
Insider Trades by Quarter for Salix Pharmaceuticals (NASDAQ:SLXP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/6/2015Timothy J CreechInsiderSell4,600$157.67$725,282.00View SEC Filing  
3/6/2015William P ForbesEVPSell20,000$157.96$3,159,200.00View SEC Filing  
11/12/2014William P ForbesEVPSell11,079$95.05$1,053,058.95View SEC Filing  
6/26/2014Carolyn J LoganCEOSell53,057$123.38$6,546,172.66View SEC Filing  
4/22/2014Alonzo Thomas DDirectorSell11,530$110.89$1,278,561.70View SEC Filing  
1/10/2014Alonzo Thomas DDirectorSell12,050$91.83$1,106,551.50View SEC Filing  
1/9/2014Adam DerbyshireCFOSell30,001$91.48$2,744,491.48View SEC Filing  
1/8/2014William ForbesEVPSell8,000$90.06$720,480.00View SEC Filing  
1/7/2014Rick ScruggsEVPSell8,463$88.31$747,367.53View SEC Filing  
1/7/2014William KeaneDirectorSell22,500$88.31$1,986,975.00View SEC Filing  
7/24/2013William P ForbesEVPSell12,000$70.93$851,160.00View SEC Filing  
4/10/2013William P ForbesEVPSell8,673$49.37$428,186.01View SEC Filing  
12/26/2012Adam C DerbyshireCFOSell60,000$41.44$2,486,400.00View SEC Filing  
11/13/2012Mark A SirgoDirectorSell3,450$40.53$139,828.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Salix Pharmaceuticals (NASDAQ:SLXP)
Latest Headlines for Salix Pharmaceuticals (NASDAQ:SLXP)
Source:
DateHeadline
americanbankingnews.com logoReviewing Salix Pharmaceuticals (SLXP) and Rockwell Medical (RMTI)
www.americanbankingnews.com - June 29 at 8:10 AM
americanbankingnews.com logoSomewhat Favorable Media Coverage Extremely Likely to Impact Salix Pharmaceuticals (SLXP) Stock Price
www.americanbankingnews.com - May 4 at 2:32 PM
finance.yahoo.com logoValeant Pharmaceuticals Intl Inc (VRX) To Retain Salix Pharmaceuticals, Ltd. (SLXP) After Negotiations With Takeda Pharmaceutical Co Ltd (ADR) (TKPYY) Collapse
finance.yahoo.com - April 24 at 11:31 AM
americanbankingnews.com logoSalix Pharmaceuticals (SLXP) Getting Very Favorable Press Coverage, Study Finds
www.americanbankingnews.com - April 19 at 10:29 AM
benzinga.com logoBill Ackman To Investors: 'Deeply And Profoundly' Sorry For The Valeant Fiasco
www.benzinga.com - March 31 at 1:09 AM
marketwatch.com logoValeant stock falls 5% after company files 10-K
www.marketwatch.com - March 1 at 8:14 PM
finance.yahoo.com logoBill Ackman's nightmare stock is getting stomped for the 2nd day in a row
finance.yahoo.com - March 1 at 8:14 PM
wsj.com logo[$$] Allergan Admits to Disclosure Violations During Valeant Bid
www.wsj.com - February 9 at 4:24 AM
blogs.barrons.com logoValeant Pharmaceuticals: We Were Wrong, Morgan Stanley Says
blogs.barrons.com - December 16 at 3:56 AM
us.rd.yahoo.com logoWhy Valeant is Crumbling
us.rd.yahoo.com - December 1 at 1:11 AM
blogs.barrons.com logoValeant: First No Salix Sale, Now the SEC Sees Accounting Issues?!?!
blogs.barrons.com - November 30 at 8:09 PM
finance.yahoo.com logoValeant, Salix, Sales Force and Asset Sales
finance.yahoo.com - November 30 at 8:09 PM
blogs.barrons.com logoUh Oh, Valeant's Hiring. Why That's Very Bad News.
blogs.barrons.com - November 30 at 10:42 AM
bloomberg.com logoValeant's Asset Sale Clock is Ticking
www.bloomberg.com - November 21 at 12:47 PM
fool.com logoIs Valeant Pharmaceuticals the Turnaround Opportunity of a Lifetime?
www.fool.com - November 18 at 7:07 PM
ft.com logo[$$] New Valeant chief nurses $1.3m paper loss on shares
www.ft.com - November 13 at 11:23 AM
thestreet.com logoAckman: Valeant Can Sell Non-Core Assets to Reduce Debt
www.thestreet.com - November 10 at 7:29 PM
fool.com logoSelling Salix Could Be the Most "Valeant" Move Ever
www.fool.com - November 9 at 7:34 PM
fool.com logoValeant Pharmaceuticals Just Delivered a Trifecta of Bad News in Its Q3 Report
www.fool.com - November 9 at 10:15 AM
bloomberg.com logoValeant's Possible Fire Sale Looks Worse Than Ever
www.bloomberg.com - November 8 at 7:24 PM
finance.yahoo.com logoValeant adj profit misses estimates; FY forecast cut
finance.yahoo.com - November 8 at 11:22 AM
ft.com logo[$$] Valeant shares fall after sales and earnings targets cut
www.ft.com - November 8 at 11:22 AM
thestreet.com logoAnalysts Remain Wary Ahead of Valeant Earnings
www.thestreet.com - November 7 at 8:23 PM
marketwatch.com logoValeant earnings: Expect an update on plans to sell Salix
www.marketwatch.com - November 7 at 8:23 PM
ft.com logo[$$] Valeant: I love you, you pay my rent
www.ft.com - November 2 at 7:51 PM
fool.com logoNegative Analyst Commentary Pushes Valeant Pharmaceuticals Intl. Inc. Lower by 11%
www.fool.com - November 2 at 7:51 PM
blogs.barrons.com logoValeant: A Good Strategic Move?
blogs.barrons.com - November 2 at 7:51 PM
blogs.barrons.com logoValeant: Selling Salix a Warning of Trouble to Come?
blogs.barrons.com - November 2 at 11:02 AM
bloomberg.com logoHold the Valeant Applause
www.bloomberg.com - November 2 at 11:02 AM
bizjournals.com logoValeant gets new approval for legacy Salix drug
www.bizjournals.com - July 20 at 1:50 PM
thestreet.com logoValeant's Drug Approvals May Save the Day
www.thestreet.com - July 20 at 12:30 PM
fool.com logoHow Much Is Valeant Pharmaceuticals Really Worth?
www.fool.com - June 17 at 2:41 PM
bizjournals.com logoDetails of kickbacks and fraud emerge in Valeant's Salix unit settlement
www.bizjournals.com - June 10 at 11:55 AM

Social

Chart

Salix Pharmaceuticals (SLXP) Chart for Tuesday, July, 25, 2017

This page was last updated on 7/25/2017 by MarketBeat.com Staff